Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Thumbprints: Biological Signatures That Measure Loss of Identity.

Biomolecules·2024
Same author

Editorial: Streaming inflammation: From damage to healing and resilience-Volume II.

Frontiers in pharmacology·2023
Same author

Editorial: Streaming Inflammation: From Damage to Healing and Resilience.

Frontiers in pharmacology·2022
Same author

Scientific and Artful Voices of Resilience.

Frontiers in pharmacology·2021
Same author

The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond.

Frontiers in pharmacology·2018
Same author

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

Journal of the American College of Cardiology·2008
Same journal

EDITORIAL INTRODUCTION.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Exploring the role of parathyroid hormone in sarcopenia: A review.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Normocalcemic primary hyperparathyroidism: an update on diagnostic and management challenges.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Prediabetes before pregnancy: implications for risk stratification and research.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Secondary hyperparathyroidism in chronic kidney disease: update on pathophysiology and new treatment targets.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Revisiting the relationship between weight loss and bone health in people living with obesity: insights from the latest evidence.

Current opinion in endocrinology, diabetes, and obesity·2026
See all related articles

Related Experiment Video

Updated: Jul 7, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Glitazones and the cardiovascular system.

Pallavi R Devchand1

  • 1Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine, Brigham & Women's Hospital, Harvard University, Boston, Massachusetts 02115, USA. pdevchand@rics.bwh.harvard.edu

Current Opinion in Endocrinology, Diabetes, and Obesity
|March 5, 2008
PubMed
Summary
This summary is machine-generated.

Glitazone drugs like rosiglitazone and pioglitazone show promise for type 2 diabetes and insulin resistance. However, cardiovascular safety concerns, particularly with rosiglitazone, warrant further investigation into their molecular mechanisms.

Related Experiment Videos

Last Updated: Jul 7, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Type 2 diabetes affects over 160 million people globally.
  • Glitazones (rosiglitazone, pioglitazone) are insulin-sensitizing oral antidiabetic drugs.
  • Cardiovascular abnormalities are common in insulin resistance.

Purpose of the Study:

  • To review recent advancements in understanding the cardiovascular molecular mechanisms of rosiglitazone and pioglitazone.
  • To address the unresolved questions regarding the cardiovascular safety of glitazone drugs.

Main Methods:

  • Review of recent meta-analyses on glitazone cardiovascular effects.
  • Examination of data regarding rosiglitazone's potential for myocardial ischemia.
  • Analysis of the shared and distinct molecular actions of rosiglitazone and pioglitazone.

Main Results:

  • Meta-analyses on rosiglitazone's cardiovascular safety remain inconclusive regarding myocardial ischemia.
  • The US FDA issued a black box warning for rosiglitazone (Avandia) due to potential risks of myocardial infarction and heart-related deaths.
  • The precise molecular mechanisms and extent of shared actions between rosiglitazone and pioglitazone are not fully elucidated.

Conclusions:

  • There is an urgent need to clarify the molecular mechanisms of rosiglitazone and pioglitazone.
  • Understanding these mechanisms is crucial for assessing the cardiovascular impact on patients with type 2 diabetes.
  • Further research is required to resolve cardiovascular safety concerns associated with glitazone therapy.